Biopharmaceuticals for prevention of COVID-19: A scoping review

导出学术成果认领

摘要The COVID-19 epidemic caused by SARS-CoV-2 virus has turned into a worldwide pandemic. Therefore, health officials all around the world have strived for developing efficient preventive and treatment methods to deal with this global crisis. Amongst them, monoclonal antibodies, anti-TNFs, and convalescent plasma appear to be effective against this disease. In addition, clinical trials are currently being conducted for viral targeting vaccines. This review summarizes major advances using biopharmaceuticals in the treatment and prevention strategies against COVID-19 that have occurred in the global medicinal system from its introduction until March 2022.

作者 Afsaneh Farjami ^[1] Soheila Montazersaheb ^[2] Saiedeh Razi Soofiyani ^[3] Parvin Akbarzadehlaleh ^[4] Sara Salatin ^[5] 学术成果认领

作者单位 Food and Drug Safety Research Center, Tabriz University of Medical Science, Tabriz, Iran;Pharmaceutical Analysis Research Center, Tabriz University of Medical Science, Tabriz, Iran ^[1] Molecular Medicine Research Center, Tabriz University of Medical Science, Tabriz, Iran ^[2] Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;Clinical Research Development Unit Sina Educational, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran ^[3] Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran ^[4] Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran ^[5]

关键词 COVID-19 SARS-CoV-2 Biopharmaceuticals Monoclonal antibodies Anti-TNFs Convalescent plasma Vaccine

栏目名称

Review Article

DOI 10.4103/1995-7645.348158

发布时间 2022-07-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交